Graft Versus Host Disease Clinical Trial
Official title:
Lymphocyte Profiles and Activation Status in the Development of Chronic Graft-versus-Host Disease
This research trial studies lymphocyte profiles and activation status in patients with graft-versus-host disease. Studying samples of blood in the laboratory from patients with cancer may help doctors identify and learn more about biomarkers related to graft-versus-host disease.
PRIMARY OBJECTIVES:
I. To explore and assess changes in subsets and activation status of B-, T,-, and natural
killer (NK) lymphocytes in peripheral blood following allogeneic stem cell transplant and
how they may be associated with clinical events with an ultimate future goal of conducting a
larger successor study to identify potential therapeutic targets based on its findings.
SECONDARY OBJECTIVES:
I. To assess the feasibility of obtaining and comparing patients with chronic
graft-versus-host disease (cGVHD) with time-matched stem cell transplant (SCT) patients
without cGVHD and identify logistical challenges with obtaining and processing samples in
each of the subgroups of interest for these analyses.
II. To assess and explore differences in lymphocyte subsets (B-, T-, and NK) between those
with vs. without cGVHD.
III. To assess and explore differences in cytokines in patients with cGVHD vs. those
without.
IV. To describe lymphocyte subsets and activation and explore how these may be related to
specific clinical manifestations of cGVHD.
OUTLINE:
Blood samples are analyzed for activation status of B lymphocytes, T lymphocytes, and NK
lymphocytes via flow cytometry, enzyme-linked immunosorbent assay (ELISA), enzyme-linked
immunosorbent spot (ELISPOT), immunoblot, and microarray assays.
;
Observational Model: Case Control, Time Perspective: Cross-Sectional
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03357159 -
Anti T-lymphocyte Immunoglobulin With Post Transplant Cyclophosphamide to Prevent GVHD Post Allogeneic Transplantation
|
Phase 2 | |
| Completed |
NCT00003270 -
Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer
|
Phase 2 | |
| Terminated |
NCT02877082 -
Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients
|
Phase 2 | |
| Recruiting |
NCT01385124 -
Cannabidiol for Graft Versus Host Disease (GVHD) Prophylaxis in Allogeneic Stem Cell Transplantation
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT01616680 -
Brentuximab Vedotin in Treating Patients With Steroid-Resistant Acute Graft-Versus-Host Disease
|
Phase 2 | |
| Recruiting |
NCT01810926 -
T&B Depletion Non Malignant
|
Phase 2 | |
| Completed |
NCT01379209 -
Intravenous Administration of RGI-2001 in Patient Undergoing Allogenic Hematopoietic Stem Cell Transplantation (AHSCT)
|
Phase 1/Phase 2 | |
| Completed |
NCT01233921 -
Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer
|
N/A | |
| Recruiting |
NCT00986557 -
T-Lymphocyte Infusion or Standard Therapy in Treating Patients at Risk of Cytomegalovirus Infection After a Donor Stem Cell Transplant
|
Phase 2 | |
| Enrolling by invitation |
NCT00972660 -
Safety and Efficacy Study of Allogenic Mesenchymal Stem Cells to Treat Extensive Chronic Graft Versus Host Disease
|
Phase 2 | |
| Terminated |
NCT00555048 -
Alemtuzumab, Busulfan, and Cyclophosphamide Followed By a Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
|
Phase 1/Phase 2 | |
| Terminated |
NCT00373815 -
Everolimus in Combination With Cyclosporine A and Prednisolone for the Treatment of Graft Versus Host Disease
|
Phase 1 | |
| Terminated |
NCT00608517 -
Treatment of Single or Double Umbilical Cord Trans + Graft-versus-host Disease (GVHD) Prophylaxis w/ Tacrolimus & Mycophenolate Mofetil
|
N/A | |
| Completed |
NCT00056875 -
Recombinant Human Keratinocyte Growth Factor in Unrelated and Related Transplants
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05808985 -
Intestinal Microbiome-based Research for the Prevention of Acute GVHD
|
Phase 2 | |
| Completed |
NCT00813618 -
Study of MEDI 507 in the Treatment of Pediatric Patients
|
Phase 1 | |
| Completed |
NCT00003398 -
Bone Marrow Transplantation in Treating Patients With Hematologic Cancer
|
Phase 4 | |
| Terminated |
NCT00005641 -
Removal of T Cells to Prevent Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation
|
Phase 2 | |
| Completed |
NCT02663622 -
Phase II Trial of Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft-Versus-Host Disease (GVHD) Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-002)
|
Phase 2 | |
| Completed |
NCT00577278 -
A Phase II Study of Allo-HCT for B-Cell NHL Using Zevalin, Fludarabine and Melphalan
|
Phase 2 |